Cancer Driver Interception – Advanced diagnostic monitoring for early cancer prevention.
HELIXAFE
Intercepting Cancer Before It Develops
HELIXAFE represents a revolutionary approach to cancer prevention through the continuous monitoring of key biological drivers that precede cancer development. Rather than detecting cancer after it has formed, HELIXAFE intercepts the conditions that enable cancer to arise.
Modern oncology research has identified four critical biological imbalances that create the environment for cancer development: chronic inflammation, microbiome dysbiosis, genomic instability, and immune system dysfunction. When these conditions persist over time, they significantly increase cancer risk.
The HELIXAFE protocol provides comprehensive, periodic monitoring of these four cancer drivers through specialized diagnostic tests. By tracking changes in these biomarkers over time, we can identify concerning trends early and implement targeted interventions before cancer has a chance to develop.
The Four Cancer Drivers We Monitor
Scientific research has established clear links between these biological conditions and cancer development. HELIXAFE monitors each driver through dedicated diagnostic protocols.
Chronic Inflammation
Pro-inflammatory cytokines create a tumor-promoting microenvironment and DNA damage.
Microbiome Dysbiosis
Pathogenic bacteria produce carcinogenic metabolites and significantly impair immune surveillance.
Genomic Instability
Accumulating DNA mutations and chromosomal aberrations are hallmarks of cancer initiation.
Immune Dysfunction
Weakened immune surveillance allows pre-cancerous cells to escape detection and elimination.
The clinical utility of the HELIXAFE protocol was demonstrated in a study published in the scientific journal Cell Death & Disease by an international group of experts coordinated by researchers from Bioscience Genomics, a spin-off jointly owned by the University of Rome “Tor Vergata” and Bioscience Institute.
The HELIXAFE protocol was presented during a Consensus Conference held at the Senate of the Italian Republic. Read the White Paper.
HELIXAFE Diagnostic Protocols
Each HELIXAFE protocol is designed to comprehensively assess one of the four cancer drivers through advanced biomarker analysis and cutting-edge diagnostic technologies.
CYTOBALANCE
Pro-inflammatory Cytokine Monitoring – Comprehensive analysis of inflammatory biomarkers including IL-2, IL-6, IL-10, TNF-α and more.
MICROBALANCE
Gut and Vaginal Microbiome Assessment – Advanced metagenomic sequencing to evaluate microbial composition and detect dysbiosis patterns.
HELIXBALANCE
Genome Instability Monitoring – Liquid biopsy analysis detecting circulating tumor DNA, chromosomal aberrations and mutation signatures.
IMMUNEBALANCE
Immune System Balance Analysis – Complete immunophenotyping and functional assessment of innate and adaptive immune responses.
Explore Each Protocol in Detail
Click on each protocol to learn more about the biomarkers analyzed, testing methodology, and clinical significance.
CYTOBALANCE – Pro-inflammatory Cytokine Monitoring
Target: Chronic low-grade inflammation (Inflammaging)
Test Type: Blood serum analysis with multiplex cytokine assay
Description:
CYTOBALANCE provides a comprehensive assessment of the inflammatory status by measuring key pro-inflammatory and anti-inflammatory cytokines. Chronic inflammation is recognized as a major driver of cancer development, creating a microenvironment that promotes tumor initiation and progression.
Biomarkers Analyzed:
- IL-2: T-cell activation and proliferation marker
- IL-4: Th2 immune response indicator
- IL-6: Major pro-inflammatory cytokine linked to cancer progression
- IL-10: Anti-inflammatory cytokine for immune balance assessment
- IL-12: Th1 response and anti-tumor immunity marker
- IL-17A: Inflammatory response associated with autoimmunity
- IFN-γ: Interferon gamma for cellular immunity assessment
- TNF-α: Key inflammatory mediator in cancer microenvironment
- hs-CRP: High-sensitivity C-reactive protein for systemic inflammation
Clinical Significance:
Elevated inflammatory markers indicate increased cancer risk and guide targeted anti-inflammatory interventions. Serial monitoring tracks treatment response and identifies emerging inflammation patterns.
Discover CYTOBALANCE
MICROBALANCE – Gut and Vaginal Microbiome Assessment
Target: Microbiome dysbiosis and pathogenic colonization
Test Type: Metagenomic sequencing of stool and/or vaginal samples
Description:
MICROBALANCE uses advanced next-generation sequencing to comprehensively characterize the gut and vaginal microbiome. Dysbiosis has been linked to multiple cancer types including colorectal, gastric, and cervical cancers through mechanisms involving inflammation, metabolite production, and immune modulation.
Analysis Components:
- Bacterial Diversity Indices: Alpha and beta diversity measurements
- Taxonomic Profiling: Species-level identification and relative abundance
- Pathogenic Bacteria Detection: Identification of cancer-associated bacteria
- Beneficial Bacteria Assessment: Evaluation of protective microbial populations
- Functional Pathway Analysis: Metabolic capacity and potential metabolite production
- Dysbiosis Index: Quantitative measure of microbiome imbalance
Clinical Significance:
Identifies cancer-promoting bacterial signatures and guides targeted probiotic/prebiotic interventions. Vaginal microbiome assessment is particularly relevant for cervical cancer risk stratification.
Discover MICROBALANCE
HELIXBALANCE – Genome Instability Monitoring
Target: DNA damage, mutations, and chromosomal aberrations
Test Type: Liquid biopsy with circulating cell-free DNA analysis
Description:
HELIXBALANCE employs cutting-edge liquid biopsy technology to detect signs of genomic instability before cancer develops. By analyzing cell-free DNA fragments circulating in the bloodstream, we can identify mutation signatures, chromosomal copy number variations, and methylation changes indicative of pre-cancerous processes.
Analysis Components:
- Circulating Tumor DNA (ctDNA): Detection of cancer-associated mutations
- Copy Number Variations: Chromosomal gains and losses analysis
- Mutation Signature Analysis: Identification of mutagenic exposure patterns
- Methylation Profiling: Epigenetic changes associated with cancer development
- Fragmentation Patterns: cfDNA fragment size distribution analysis
- Multi-Cancer Early Detection: Pan-cancer signal assessment
Clinical Significance:
Provides the earliest possible detection of genomic changes that precede cancer formation. Enables risk stratification and guides preventive interventions at the molecular level.
Discover HELIXBALANCE
IMMUNEBALANCE – Immune System Balance Analysis
Target: Immune dysfunction and immunosenescence
Test Type: Flow cytometry immunophenotyping and functional assays
Description:
IMMUNEBALANCE provides a comprehensive evaluation of immune system status, assessing both innate and adaptive immunity. Immune surveillance is critical for eliminating pre-cancerous cells, and age-related immune decline (immunosenescence) significantly increases cancer risk.
Analysis Components:
- T-Cell Subsets: CD4+, CD8+, regulatory T-cells, memory and naive populations
- B-Cell Populations: Mature, memory, and plasma cell assessment
- NK Cell Activity: Natural killer cell numbers and cytotoxic function
- Monocyte/Macrophage Profiling: M1/M2 polarization status
- Immune Checkpoint Expression: PD-1, CTLA-4, and other checkpoint markers
- Functional Capacity: Proliferation and cytokine production assays
- Immunosenescence Markers: Immune aging indicators
Clinical Significance:
Identifies immune deficiencies that impair cancer surveillance and guides immunomodulatory interventions. Essential for monitoring immune reconstitution and optimizing immune health.
Discover IMMUNEBALANCE
The Cancer Driver Interception Approach
HELIXAFE represents a paradigm shift from reactive cancer detection to proactive cancer prevention. Our integrated approach combines regular monitoring with personalized intervention strategies.
Continuous Monitoring
Regular periodic testing tracks biomarker trends over time, identifying concerning changes before they become clinical problems.
Personalized Intervention
Based on your unique biomarker profile, we develop targeted strategies using nutraceuticals, lifestyle modifications, and advanced therapies.
Outcome Tracking
Follow-up assessments measure intervention effectiveness and consistently adjust protocols based on your body’s individual response to treatment.
HELIXAFE integrates seamlessly with Bioscience Institute’s food supplements (CYTODRIVE, MICRODRIVE, HELIXDRIVE, IMMUNEDRIVE) and advanced therapeutic services. When biomarker imbalances are detected, targeted interventions can be implemented immediately, creating a closed-loop system for cancer prevention and optimal health maintenance.
